Michael Chadham Nivens,Thierry Bouyssou,Peter Seither,Rolf Goeggel
申请号：
US15658918
公开号：
US20170319567A1
申请日:
2017.07.25
申请国别(地区):
US
年份:
2017
代理人:
摘要：
The present invention relates to CCR3 inhibitors of formula 1,whereinR1 is H, C1-6-alkyl, C0-4-alkyl-C3-6-cycloalkyl, C1-6-haloalkyl；R2 is H, C1-6-alkyl；X is an anion selected from the group consisting of chloride or ½ dibenzoyltartratej is 1 or 2.for use as a medicament for the treatment of diseases selected from dry age-related macular degeneration (dAMD), wet age-related macular degeneration (wAMD), retinopathy of prematurity (ROP), central retinal vein occlusion (CRVO), nasal polyposis, eosinophilic esophagitis, eosinophillic gastroenteritis (e.g. eosinophilic gastritis and eosinophilic ententeritis), hypereosinophilic syndrome and Churg Strauss syndrome.
